-
The tiny stocks you'll be talking about in ten years' time
Features Most penny stocks go unnoticed by investors. But if you get in early, says Tom Bulford, you can hitch a ride as the corporate giants of tomorrow knock old industries aside or build new ones from scratch.
Features -
The British recovery will start here
Features There is a particular place where penny share expert Tom Bulford regularly finds great companies. He calls it the ‘new cradle of British industry’.
Features -
Why biotech is fast becoming the story of 2012
Features Professional investors are piling into biotech stocks - and hoping you won't notice, says Tom Bulford. So, don't miss out on what’s fast becoming the investment story of the year.
Features -
Things are looking up for this biotech
Tutorials When a company's shareholders are asked to pump more cash into the business, it's often bad news. But in the case of this small biotech firm, it could turn out to be a very profitable deal, says Bengt Saelensminde.
Tutorials -
The great technology story to replace the digital boom
Features Digital media was the great tech story of the last decade. But now there's a new tech story emerging, says Tom Bulford - and this one promises to be even more exciting.
Features -
Agreed bid for AGI Therapeutics
News Pharmaceutical company AGI Therapeutics is to be swallowed up by Aravis Therapeutics, a recently formed Irish subsidiary of Altiva.
News -
Glaxo to submit Relovair to regulatory authorities
News Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-a-day respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
News -
GlaxoSmithKline set to submit Relovair to regulators
News Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-daily respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
News -
Earnings at the lower end of forecasts, says AstraZeneca
News Biopharmaceutical giant AstraZeneca has said that full-year earnings are now expected to come in at the lower end of previous guidance.
News